-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, TIK3XMfvNUKEm9a0acLITeXxIEJ+S093NiB1xKJcKmmCtXY+gUUXOQ+Jtw/+PgWe SZzmSgt9NpxUtW/Mbi4cGQ== 0001036050-99-002466.txt : 19991202 0001036050-99-002466.hdr.sgml : 19991202 ACCESSION NUMBER: 0001036050-99-002466 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 19991201 FILED AS OF DATE: 19991201 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PHOENIX INTERNATIONAL LIFE SCIENCES INC CENTRAL INDEX KEY: 0000935016 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 223209631 FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 6-K SEC ACT: SEC FILE NUMBER: 000-29942 FILM NUMBER: 99767381 BUSINESS ADDRESS: STREET 1: 2350 COHEN STREET STREET 2: ST LAURENT QUEBEC CITY: H4R 2P7 CANADA STATE: A8 ZIP: 00000 6-K 1 PHOENIX INTERNATIONAL LIFE SCIENCES, INC FORM 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Dated December 1, 1999 PHOENIX INTERNATIONAL LIFE SCIENCES INC. ---------------------------------------- (Translation of registrant's name into English) 2350 Cohen Street ----------------- Saint Laurent, Quebec Canada H4R 2N6 ------------------------------------ (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ______ Form 40-F X (commenced in calendar ----- year 1998) Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes ____ No X --- If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): ______________ SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PHOENIX INTERNATIONAL LIFE SCIENCES INC. ---------------------------------------- (Registrant) Date: December 1, 1999 By: /s/ David Moszkowski ----------------- ----------------------------------- David Moszkowski Senior Vice President and Chief Financial Officer EX-99.1 2 PRESS RELEASE DATED 11/29/99 Exhibit 99.1 PHOENIX INTERNATIONAL RE-ALIGNS GLOBAL OPERATIONS -- Company is focused on the integration of its global operations to better serve its customers and realize improved operating efficiencies -- Montreal, Quebec - November 29, 1999 - Phoenix International Life Sciences Inc. (NASDAQ: PHXI; TSE/ME: PHX), one of the world's top five Contract Research Organizations (CROs), today announced that it is re-aligning its global operations to better serve its international customers, improve its operating efficiencies and meet anticipated future growth in demand for its services. Under the direction of recently appointed CEO, Ian Lennox, Phoenix International will now comprise four fully integrated global service units: . Discovery and Preclinical Services, headed by Dr. Nigel Brown; . Global Analytical and Phase I Services, headed by Dr. Stephane Huguet; . Clinical Research, Americas, headed by Dr. Susan Thornton; . Clinical Research, Europe/Asia, headed by Dr. Lucien Steru. Phoenix International's new service units will be supported by David Moszkowski, Finance, Tax, & Treasury, George Engelberg, Information Technology, and a small corporate services group. "Our new business structure will enable better allocation of people and capital as we shift the company from a geographically independent group of business entities, to a fully integrated, global CRO," said Ian Lennox. "The re-alignment will offer our customers improved access to our global services." This new strategic organizational structure is designed to consolidate and leverage the company's acquisitions to improve its overall operations and profitability. Customer service will be enhanced through greater flexibility, improved efficiencies and better allocation of resources. -- more -- About Phoenix International Phoenix International is one of the world's leading contract research organizations. The Company provides a wide spectrum of clinical, analytical, preclinical, drug discovery support and ancillary services to the pharmaceutical and biotechnology industries. Since beginning its operations in 1989, Phoenix International has grown to approximately 2,400 employees worldwide, of whom more than 215 have either medical degrees or PhD's and over 240 others have masters level education. Headquartered in Montreal, Quebec, Phoenix International has operations throughout Europe and North America and research facilities in Australia, Israel and South Africa. Phoenix International is on the World Wide Web at www.pils.com. ------------ This release contains "forward-looking" statements regarding future results and events, including statements regarding expected future revenues, earnings and growth rates and goals and operating plans of management. Phoenix's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Factors that may cause such a difference include, but are not limited to: the inability of Phoenix to win new business at the levels required; the cancellation or delay of contracts; risks associated with the management of growth and the ability to attract and retain employees; risks of integrating newly acquired businesses; competition; any claims for patent infringement; unanticipated costs in connection with Year 2000 conversion; the ability to obtain future financing; adverse regulatory developments; foreign exchange rate fluctuations; and uncertainty surrounding the Euro. FOR MORE INFORMATION, PLEASE CONTACT: Richard Gareau Director, Corporate Communications Phoenix International Life Sciences Inc. Tel: (514) 333-0033 Fax: (514) 333-8861 E-mail: gareaur@pils.com EX-99.2 3 PRESS RELEASE DATED 11/30/99 Exhibit 99.2 PRESS RELEASE PHOENIX INTERNATIONAL RE-ALIGNS UK OPERATIONS MONTREAL, QUEBEC - NOVEMBER 30, 1999 - Phoenix International Life Sciences Inc. (NASDAQ: PHXI; TSE/ME: PHX), one of the world's top five Contract Research Organizations (CROs), announced today that it is re-aligning its UK operations to improve efficiency and better serve the future needs of its customers. This local initiative is a further development of the Company's global re- alignment into four fully-integrated service units. The UK operations will be relocating to a more accessible site closer to Heathrow Airport and its key customers to accommodate its growing international business. 'The UK re-alignment will continue the building of our strong management team and business development capabilities in the United Kingdom. These changes will provide the foundation to accommodate profitable growth,' said Ian Lennox, Chief Executive Officer of Phoenix International. Commenting on the initiative, Lucien Steru, Head of Clinical Research, Europe/Asia, Phoenix International, stated: 'This re-alignment will ensure that as we grow, we will continue to provide our customers with efficient, high quality services. Our new facility will be better located and will enable us to recruit additional highly qualified staff.' Simon Yaxley, recently appointed Managing Director of Phoenix's UK operations, will spearhead the drive to establish a stronger operation in the UK. Currently, the Romford operations employ over 75 specialized staff working in Phase II-IV clinical trials, in ClinQA, the independent in-house quality assurance division, and Rostrum the training division. About Phoenix International Phoenix International is one of the world's leading contract research organizations. The Company provides a wide spectrum of clinical, analytical, preclinical, drug discovery support and ancillary services to the pharmaceutical and biotechnology industries. Since beginning its operations in 1989, Phoenix International has grown to approximately 2,400 employees worldwide, of whom more than 215 have either medical degrees or PhD's and over 240 others have masters level education. Headquartered in Montreal, Quebec, Phoenix International has operations throughout Europe and North America and research facilities in Australia, Israel and South Africa. Phoenix International is on the World Wide Web at www.pils.com. ------------ This release contains "forward-looking" statements regarding future results and events, including statements regarding expected future revenues, earnings and growth rates and goals and operating plans of management. Phoenix's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Factors that may cause such a difference include, but are not limited to: the inability of Phoenix to win new business at the levels required; the cancellation or delay of contracts; risks associated with the management of growth and the ability to attract and retain employees; risks of integrating newly acquired businesses; competition; any claims for patent infringement; unanticipated costs in connection with Year 2000conversion; the ability to obtain future financing; adverse regulatory developments; foreign exchange rate fluctuations; and uncertainty surrounding the Euro. -30- FOR MORE INFORMATION, PLEASE CONTACT: Richard Gareau Director, Corporate Communications Phoenix International Life Sciences Inc. Tel: (514) 333-0033 Fax: (514) 333-8861 E-mail:gareaur@pils.com -----END PRIVACY-ENHANCED MESSAGE-----